Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15455484 | 0.94 | CYP3A4 (0.37) | CYP3A4TSHRTDP1ALDH1A1HPGD | |
| SCHEMBL13278178 | 0.93 | GABRA1 (0.48) | CYP3A4TSHRTDP1ALDH1A1HPGD | |
| SCHEMBL14994029 | 0.89 | NOTUM (0.49) | NOTUMKDR | |
| SCHEMBL548187 | 0.85 | GABRA1 (0.45) | CYP3A4TSHRTDP1ALDH1A1HPGD | |
| SCHEMBL31075912 | 0.84 | NOTUM (0.33) | CYP3A4TSHRTDP1ALDH1A1HPGD | |
| SCHEMBL20569873 | 0.84 | MEN1 (0.37) | CYP3A4TSHRTDP1ALDH1A1HPGD | |
| SCHEMBL309871 | 0.82 | CA1 (0.41) | CYP3A4ALDH1A1HSD17B10NOTUM | |
| SCHEMBL15456773 | 0.79 | ALDH1A1 (0.39) | ALDH1A1NOTUM | |
| SCHEMBL3072277 | 0.79 | NOTUM (0.45) | CYP3A4TDP1ALDH1A1HPGDALOX15 | |
| SCHEMBL18802839 | 0.77 | ALOX15 (0.46) | CYP3A4TSHRTDP1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113727970-B | Maleimide, curable resin composition, and cured product | DIC株式会社 | 2024-11-15 | — | — | CN | disclosed |
| CN-113767130-B | Curable resin composition | DIC株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-113748149-B | Curable resin composition | DIC株式会社 | 2024-05-24 | — | — | CN | disclosed |
| CN-113767117-B | Curable resin composition | DIC株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-113748152-B | Curable resin composition | DIC株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-113728030-B | Curable resin composition | DIC株式会社 | 2023-08-15 | — | — | CN | disclosed |
| US-20230159695-A1 | CURABLE RESIN, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | DIC CORPORATION (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11548844-B2 | Monomer, polymer, negative resist composition, photomask blank, and resist pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-110526802-B | Monomer, polymer, negative resist composition, photomask blank, and resist pattern forming method | 信越化学工业株式会社 | 2022-09-20 | — | — | CN | disclosed |
| EP-3572876-B1 | MONOMER, POLYMER, NEGATIVE RESIST COMPOSITION, PHOTOMASK BLANK, AND RESIST PATTERN FORMING PROCESS | SHINETSU CHEMICAL CO (JP) | 2021-04-14 | — | — | EP | disclosed |
| CN-101421252-B | 2, 6-substituted-4-monosubstituted aminopyrimidines as prostaglandin D2 receptor antagonists | SANOFI AVENTIS | 2011-10-12 | — | — | CN | disclosed |
| CN-101421252-A | 2, 6-substituted-4-monosubstituted aminopyrimidines as prostaglandin D2 receptor antagonists | SANOFI AVENTIS (FR) | 2009-04-29 | — | — | CN | disclosed |
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| US-7005216-B2 | Photo mask | RENESAS TECHNOLOGY CORP. (JP) | 2006-02-28 | — | — | US | disclosed |
| US-6790564-B2 | FOR USE IN PRODUCING SEMICONDUCTOR INTEGRATED CIRCUIT DEVICES; EFFICIENCY | RENESAS TECHNOLOGY CORPORATION (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030129505-A1 | Krypton fluoride laser lithography; photoresist pattern | RENESAS ELECTRONICS CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20020086222-A1 | Photomask and manufacturing method of an electronic device therewith | RENESAS ELECTRONICS CORPORATION (JP) | 2002-07-04 | — | — | US | disclosed |
| US-5399715-A | Polyamino oligomers and polymaleimide compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-21 | — | — | US | disclosed |
| EP-0577836-A1 | POLYAMINO-OLIGOMER AND POLYMALEIMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | CYP3A4 447/4885TSHR 1315/4885TDP1 2484/4885 |
| US-11548844-B2 | Monomer, polymer, negative resist composition, photomask blank, and resist pattern forming process | PARG, PCNA, PLK2 | CYP3A4 3643/4885TSHR 4309/4885TDP1 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.